Study S000140

A Randomized Phase II Study to Evaluate the Efficacy and Safety of IBI362 Versus Placebo and Dulaglutide in Chinese Patients With Type 2 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT04965506
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: DOUBLE
Status: COMPLETED
Enrollment: 252
Start: 2021-09-06
Primary completion: 2022-04-28
Lead sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Conditions: Type 2 Diabetes
Interventions: DRUG:IBI362; OTHER:placebo; OTHER:Dulaglutide
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

The change in HbA1c from baseline to 20 weeks [Baseline,20 weeks]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0012443	Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. Zhang B, Diabetes care	2024	Randomized trial	PMID 37943529 DOI	cites ClinicalTrials.gov:NCT04965506; registry reference DERIVED:37943529